“The class of cellular bone matrices has become ubiquitous in spinal surgery, yet there is no compelling data that the cells offer any clinical benefit to justify the high price point,” Jeffrey Wang, MD, co-author of the publication and director of the USC Spine Center in Los Angeles, said in a Nov. 3 news release.
The study tested CBM products both with and without the cells to allow for only one variable.
Results showed no difference in performance with or without the cells. Researchers concluded that they had no positive effect.
Additionally, researchers found that SeaSpine’s OsteoStrand Plus demineralized bone matrix product outperformed the tested CBMs in its ability to promote fusion.
More articles on biologics:
Orthopedic surgery has 3rd highest gender wage gap among medical specialties, report finds
A timeline of Medtronic’s 7 deals so far in 2020
Robots will never replace surgeons, but can prove useful partners: 3 spine surgeons weigh in
